Adenovirus purification method

Through two-step chromatography, combined with the combined use of anion exchange resin and porous shell bead resin, the adenovirus purification method has solved the purity, yield and capacity of the adenovirus purification method, and achieved efficient and safe adenovirus purification, which is suitable for adenovirus. Application as a gene delivery vector.

CN111989398BActive Publication Date: 2024-11-08CYTIVA BIOPROCESS R&D AB
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN201980028038.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-04-25
Filing Date
2019-04-24
Publication Date
2024-11-08
Estimated Expiration
2039-04-24

AI Technical Summary

Technical Problem

The existing adenovirus purification methods have insufficient purity, yield and capacity, especially when adenoviruses are used as gene delivery vectors, it is difficult to meet efficient and safe production needs.

Method used

Using two-step chromatography, adenovirus is first captured on anion exchange resin, and then refined in porous shell bead resin. The adenovirus with high purity and high yield is achieved by using shallow conductivity gradient elution and hydrophobic interaction ligands. purification. Specific steps include capturing the adenovirus on the anion exchange resin, elution using shallow conductivity gradients, and then adding the adenovirus to the shell bead resin containing a porous shell and core for further elution, ensuring a low content of the host cell protein.

Benefits of technology

Adenovirus purification with high capacity, low host cell protein (HCP) content and high purity is achieved, with a recovery rate of 80-100%, and excellent performance is maintained on the scale. It is suitable for the application of adenovirus as a cell therapy vector.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111989398B_ABST
    Figure CN111989398B_ABST
Patent Text Reader

Abstract

The present invention relates to a virus purification method. The present invention provides a downstream method for purifying adenovirus from cell culture harvest. More specifically, it relates to an adenovirus purification method using virus capture and virus polishing steps.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to a virus purification method. The present invention provides a downstream method for purifying adenovirus from cell culture harvest. More specifically, it relates to an adenovirus purification method using virus capture and virus polishing steps. Background of the Invention

[0003] Human adenoviruses have been classified into six species (A to F) with 55 known serotypes, causing illnesses ranging from mild respiratory infections in young children (known as the common cold) to life-threatening multi-organ disease in people with weakened immune systems. Adenoviruses are common pathogens that are widely used for gene delivery in oncology, cardiovascular and regenerative medicine, as well as as vaccine vectors, both experimentally and in completed and ongoing clinical trials.

[0004] Adenoviruses are being evaluated as vaccine delivery systems in many preclinical and clinical studies for various infectious diseases (Kallel, H. and Kamen, AA Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials. Biotechnol J 10, 741–747 (2015). Adenoviruses are also being explored as potential viral vectors for gene therapy and as oncolytic viruses. Several generations of recombinant adenoviral vectors have been developed to enhance productivity and produce more effective and safer vaccines (Appaiahgari, MB and Vrati, S. Adenoviruses as gene / vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther 15, 337-351 (2015). The most studied adenoviral vector is the first-generation recombinant adenovirus serotype 5 (AdV5), making it a suitable system for developing adenoviral production methods.

[0005] Chromatographic techniques are used for adenovirus purification, but the results are often inadequate in terms of purity, yield, and capacity.

[0006] Thus, there remains a need to find better and more efficient methods for adenovirus purification, especially in those cases where the virus is to be used as an adenoviral gene delivery vector. SUMMARY OF THE INVENTION

[0008] The present invention provides an efficient method for adenovirus purification with high capacity and high yield.

[0009] The present invention relates to a method for purifying adenoviruses, comprising the steps of: a) capturing adenoviruses from a cell culture harvest containing adenoviruses on an anion exchange resin; b) eluting the adenoviruses with a shallow conductivity gradient having an increasing salt concentration of 15-25%, preferably 18-20%; c) adding the eluted adenoviruses to a shell bead resin comprising a porous shell and a porous core, wherein the core is provided with a hydrophobic interaction ligand and the shell is not provided with any ligand; and d) eluting the adenoviruses from the shell bead resin into a flow-through, wherein the eluted adenoviruses in step d) contain less than 1 ng / ml of host cell proteins (HCP).

[0010] Preferably, the salt is NaCl and the gradient is an increase of 18-20% and the salt concentration is 0-700 mM, such as 480-570 mM NaCl as in the examples below, or any interval between 0-700 mM corresponding to a shallow gradient of 18-20% increase from the starting salt concentration.

[0011] Preferably, the anion exchange resin is multicomponent Capto Q ImpRes anion exchange resin and the shell bead resin is Capto Core 700 resin.

[0012] The anion exchange resin is packed in a column and the shell bead resin is packed in another column, and the eluted adenovirus is added (loaded) to the shell bead resin in a volume corresponding to 15-30 column volumes (CV), preferably 25-30 CV, of the column containing the shell bead resin. The porosity of the core and shell can be the same or different.

[0013] The adenovirus eluted in step d) is very pure and contains no detectable impurities. The level of host cell proteins (HCP) is undetectable or less than 1 ng / ml.

[0014] As shown in the experimental section, the recovery of adenovirus eluted in step d) was 80-100%.

[0015] A preferred use of adenovirus is as an adenoviral vector for cell therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 An overview of two two-step chromatographic methods (the method of the invention and the reference method) for adenovirus purification is shown.

[0018] Figure 2 Shown are chromatograms from a scaled-up method of the invention using (A) Capto Q ImpRes for the capture step and (B) Capto Core 700 for the polishing step.

[0019] Figure 3 Shown are chromatograms for a reference method using A) Sepharose QXL for the capture step and (B) Sepharose 4 FastFlow for the polishing step. DETAILED DESCRIPTION OF THE INVENTION

[0021] The present invention describes the development of a downstream chromatography step for purifying adenovirus from HEK293 cell culture harvest. After screening 10 different anion exchange or multi-resins and 1 anion exchange membrane on a small scale, two resins were selected based on the highest dynamic binding capacity. Process conditions were optimized and a polishing step was included to further reduce impurities to meet regulatory requirements. Performance was compared on a small scale for the first anion exchange capture step, followed by polishing by size exclusion or using Captocore multi-resin. Using 3 L of cell culture harvest, the reference method and the downstream method developed by the present invention were compared on a large scale. Although the overall method results showed comparable performance between the developed two-step chromatographic methods, the loading capacity was approximately 150 times that for the polishing step of the present method by using Capto core 700 resin instead of traditional size exclusion.

[0022] Materials and methods

[0023] Virus propagation and sample preparation

[0024] HEK293.2sus cells (ATCC) grown in HyClone™ CDM4HEK medium in an Xcellerex™ XDR-10 or ReadyToProcess WAVE™ 25 bioreactor system were infected with AdV5 encoding green fluorescent protein (GFP). Cells were lysed in the bioreactor with 0.5% Tween™ 20 during a 4-hour mixing period. Simultaneously, 20 U / mL Benzonase™ was added to digest host cell DNA (hcDNA). Clarification of the harvested material was performed by forward flow filtration (NFF) using a combination of ULTA™ 2 μm and 0.6 μm GF filters for removal of cell debris and preliminary impurity reduction. Tangential flow filtration (TFF) was performed on an ÄKTA™ flux 6 filtration system using a 100 μm filter cartridge with M r Hollow fiber filters with a nominal molecular weight cutoff of 300 000 were used for concentration and buffer exchange to 20 mM Tris, pH 8.0. Sodium chloride was used for sample conditioning prior to the capture step.

[0025] Development of the Adenovirus Capture Protocol

[0026] Screening for dynamic binding capacity (DBC) was performed using an ÄKTA pure 25 chromatography system in 1 mL prepacked HiTrap™ columns for the resin (RESOURCE™ Q columns for SOURCE Q15) and in 1 mL ReadyToProcess Adsorber Q capsules for the membrane. DBC was determined at different NaCl concentrations in 20 mM Tris, pH 8.0 (Table 1). Loading of samples subjected to TFF was performed with a residence time of 10 min for the column and 0.2 min for the capsule until viral breakthrough.

[0027] Optimization of elution conditions

[0028] Based on the results from the DBC screening, Capto Q, Capto Q ImpRes, Q Sepharose XL, SOURCE 15Q, and Capto adhere ImpRes resins, and ReadyToProcess Adsorber Q membranes were selected for further evaluation. Linear elution gradients were evaluated in 1 mL prepacked columns for the selected resins, and for the membranes, 1 mL membrane capsules were used. Columns and capsules were equilibrated with 20 mM Tris, pH 8.0 + 300 mM NaCl (0 mM NaCl for Capto adhere ImpRes). Sample loading was performed at 80% of DBC. Fractions were collected for analysis throughout the elution gradient, up to 700 mM NaCl.

[0029] Capto Q, Capto Q ImpRes and ReadyToProcess Adsorber Q were selected for further optimization and step elution conditions were evaluated for these adsorbents. After the loading step, a wash step with as high NaCl as possible without virus breakthrough was required, followed by a complete virus elution step with as low conductivity increase as possible to avoid co-elution of DNA with virus. The performance of ReadyToProcess AdsorberQ was evaluated with samples subjected to NFF only or NFF followed by TFF.

[0030] Evaluation of Resins for Adenovirus Polishing Steps

[0031] Capto Core 700 (pre-packed in 1 mL HiTrap columns) and Sepharose 4Fast Flow (packed in HiScale™ 16 / 40, 71 mL column volume [CV]) resins were evaluated for the polishing step. Material purified in the capture step evaluated was used as sample using Capto Q, Capto QImpRes, and ReadyToProcess Adsorber Q. 10% of the CV was loaded on Sepharose Fast Flow, and up to 30 CV was loaded on Capto Core 700. To determine the maximum possible sample loading volume at acceptable virus purity for Capto Core 700, fractions were collected throughout the sample loading phase and analyzed for impurity content.

[0032] All resins were from GE Healthcare Bio-Sciences AB.

[0033] Scale-up of adenovirus capture and polishing steps

[0034] Two methods—method 1 (=method of the present invention) using samples subjected to TFF and a combination of Capto Q ImpRes anion exchange resin and Capto Core700 resin; and a reference method using samples subjected to TFF and a combination of Sepharose QXL anion exchange and Sepharose 4 Fast Flow size exclusion chromatography (SEC) resins—were scaled up for processing 3 L of cell culture harvest. For capture, Capto Q ImpRes was packed in a HiScale 26 column (88 mL), while Sepharose QXL was packed in a HiScale 50 (249 mL). For polishing, Capto Core700 was packed in a HiScale 16 column (10 mL), and Sepharose 4 Fast Flow was packed in a HiScale 50 column (382 mL). The columns were run on an ÄKTA pure 150 system. After the polishing step, a second TFF step was included for concentration, formulation and final sterile filtration. The methods were performed in duplicate.

[0035] Analytical methods

[0036] Total viral titers in triplicate samples were analyzed by qPCR on the StepOnePlus™ Real-Time PCR System using the PureLink™ Viral RNA / DNAMini Kit, TaqMan™ Universal PCR Master Mix, and forward and reverse primers for hexon DNA and TaqMan MGB 6-FAM probe (all Applied Biosystems). Human AdV5 DNA (3.1 × 10 7 copies / mL) (ViraPur) was used as a standard.

[0037] Infectious virus titers were analyzed in triplicate samples by automated fluorescence microscopy of live cells using the IN Cell Analyzer and expressed as TCID 50 Methodology, analyze the GFP signal (encoded by the virus) in the images.

[0038] The HPLC method was used for the analysis of intact viral particles using a 1 mL Tricorn™ 5 / 50 column packed with Q Sepharose XL. Elution was performed with a NaCl gradient in 20 mM Tris, pH 7.5 at a flow rate of 1.5 mL / min.

[0039] A BCA assay kit with albumin standard (Thermo Scientific) was used to analyze total protein concentration, and total DNA was determined with Quant-iT™ PicoGreen™ dsDNA Reagent (Invitrogen). Analyses were performed in duplicate.

[0040] The concentration of host cell protein (HCP) was determined using a HEK293 HCP ELISA kit (Cygnus).

[0041] The concentration of hcDNA in triplicate samples was determined by qPCR (reagents from Applied Biosystems) using primers for GAPDH (Invitrogen) and purified HEK293 DNA as a standard. Samples were prepared using the PrepSEQ™ Residual DNA Sample Preparation Kit and the MagMax™ Express 96 Purification Instrument (Life Technologies).

[0042] Experimental Section

[0043] Experiment 1: Adenovirus capture step

[0044] A comprehensive screening of anion exchange and multivariate chromatography adsorbents was performed. The screening was performed in 1 mL HiTrap columns, which provided sufficient sample volume for virus detection with available methods. As shown below, membranes and resins based on smaller bead size and thus larger virus binding surface area provided the highest capacity (Table 1).

[0045] Table 1. DBC expressed as viral particles (vp) / mL resin

[0046]

[0047] *DBC was determined using samples from different preparations.

[0048] In linear elution gradient experiments, Capto Q ImpRes and Capto Q provided good separation of adenovirus from impurities and were therefore selected for further evaluation (not shown). Although ReadyToProcess Adsorber Q provided insufficient viral purity using a linear elution gradient (not shown), this membrane was also selected for further evaluation due to its high binding capacity.

[0049] Because it was found during process optimization that the conductivity required for complete elution of the virus was significantly higher in the step elution gradient compared to the linear elution gradient for both Capto Q and Capto Q ImpRes (not shown), a linear elution gradient was chosen for the resin because the higher the elution conductivity for the virus, the higher the risk of co-elution of the virus with the DNA. DNA is negatively charged and binds strongly to anion exchangers, and longer DNA sequences (e.g. DNA that is incompletely fragmented after Benzonase treatment) bind more strongly than shorter DNA fragments. Lower elution conductivity results in reduced hcDNA in the virus elution pool.

[0050] Experiment 2: Adenovirus fine processing steps

[0051] An adenovirus polishing step was included in the purification process to further reduce impurities. For this step, both Capto Core 700 polyplex and Sepharose 4 Fast Flow SEC resins were evaluated. Capto Core 700 consists of an inert shell and a ligand-containing core, providing dual functionality to the resin. The pores in the shell allow small proteins and impurities to enter and be captured in the core, while viral particles pass through in the flow-through.

[0052] Adenovirus recovery and purity were analyzed throughout the process steps. Sepharose 4 Fast Flow and CaptoCore 700 resins provided similar performance in terms of adenovirus purity, however, CaptoCore 700 showed a clear advantage over Sepharose 4 Fast Flow in terms of sample loading volume. Sample loading for Capto Core 700 reached 30 CV, while only 0.1 CV was loaded onto the Sepharose 4 Fast Flow column. Despite the high variability of the qPCR assay, virus recovery was also determined to be higher for Capto Core 700. The overall downstream process results for the smaller scale are summarized in Table 3.

[0053] Table 3. Results from the adenovirus fine processing step

[0054]

[0055] *Total viral titer monitored by qPCR.

[0056] Two numbers indicate that the same sample was analyzed twice.

[0057] LOD= 1 ng / ml.

[0058] Although Capto Q provided higher impurity reduction than Capto Q ImpRes, results from the polishing resin evaluation showed that Capto Core 700 reduced residual impurities in the eluate from both resins to below the limit of detection (LOD). Capto Q ImpRes was selected over Capto Q due to the higher loading capacity it provided, supporting improved process economics.

[0059] Based on these results, two parallel methods were compared: method 1 combining Capto Q ImpRes and Capto Core 700, and a reference combining Sepharose QXL and Sepharose 4 Fast Flow ( Figure 1 ).

[0060] Experiment 3: Scale-up of adenovirus purification method

[0061] Method 1 and the reference method were scaled for purification of adenovirus from 3 L cell culture harvest. Method 1 showed clear advantages over the reference method in terms of impurity reduction and yield of the polishing step, but the overall results on the scale-up experiments provided comparable results between the methods. In the scale-up experiments, the hcDNA levels in the final samples were similar.

[0062] However, method 1 reduced HCP levels to below the LOD, while in the reference method, HCP levels in the final sample averaged 22 ng / mL. The amount of total viral particles in the final sample was comparable between methods (method 1: 4.9 x 10 13 and 5.3 x 10 13 vp; reference method: 3.4 x 10 13 and 5.1 x 10 13 vp).

[0063] The chromatogram for method 1 is shown in Figure 2 , while the chromatogram for the reference method is shown in Figure 3 The results from the scale-up approach are summarized in Table 4.

[0064] Method 1 ( Figure 2 A)

[0065] Samples: Harvests subjected to NFF and TFF in 20 mM Tris, pH 8.0 + 450 mM NaCl

[0066] Resin: Capto Q ImpRes

[0067] Column: HiScale 26

[0068] Loading: 5.6 × 10 11 VP / mL resin (Q B10 80% of the total, 10 minutes residence time)

[0069] Binding buffer: 20 mM Tris, pH 8.0 + 450 mM NaCl, 2 mM MgCl2

[0070] Wash: 2 CV 20 mM Tris, pH 8.0 + 480 mM NaCl, 2 mM MgCl2

[0071] Elution buffer: 2.5 CV of 20 mM Tris, pH 8.0 + 450 to 570 mM NaCl, 2 mM MgCl2

[0072] System: ÄKTA™ pure 150

[0073] Method 1 ( Figure 2 B)

[0074] Sample: Eluate from capture step

[0075] Resin: Capto Core 700

[0076] Column: HiScale 16

[0077] Loading: 9 CV Capto Q ImpRes eluate

[0078] Buffer: 20 mM Tris, pH 8.0 + 500 mM NaCl, 2 mM MgCl2

[0079] Wash: 1.5 CV of binding buffer

[0080] System: ÄKTA pure 150

[0081] Reference method ( Figure 3 A)

[0082] Samples: Harvests subjected to NFF and TFF in 20 mM Tris, pH 8.0 + 350 mM NaCl

[0083] Resin: Q Sepharose XL

[0084] Column: HiScale 50

[0085] Loading: 8.9 × 10 11 VP / mL resin (Q B10 80% of the total, 10 minutes residence time)

[0086] Binding buffer: 20 mM NaP, pH 7.3 + 350 mM NaCl, 2 mM MgCl2, 2% sucrose

[0087] Wash: 5 CV of 20 mM NaP, pH 7.3, 350 mM NaCl, 2 mM MgCl2, 2% sucrose

[0088] Elution buffer: 20 mM NaP, pH 7.3 + 500 mM NaCl, 2 mM MgCl2, 2% sucrose

[0089] System: ÄKTA pure 150

[0090] Reference method ( Figure 3 B)

[0091] Sample: Eluate from capture step

[0092] Loading: 0.2 CV Q Sepharose XL eluate

[0093] Resin: Sepharose 4 Fast Flow

[0094] Column: HiScale 50

[0095] Loading: 0.2 CV

[0096] Buffer: 20 mM sodium phosphate, pH 7.3 + 200 mM NaCl, 2 mM MgCl2, 2% sucrose

[0097] Washing: 1.5 CV of binding buffer

[0098] System: ÄKTA pure 150

[0099] Table 4. Adenovirus recovery and purity in the method of the present invention (Method 1) and reference methods

[0100]

[0101] *Analysis is performed only once.

[0102] Two numbers indicate that the same sample was analyzed twice.

[0103] LOD= 1 ng / ml.

[0104] A shallow salt gradient of CaptoQ Impres from 480 mM to 570 mM NaCl is crucial for separating DNA fragments from virus particles. This corresponds to a 19% increase in salt concentration across the entire gradient, or a 7.5% increase in salt concentration per CV in the gradient (gradient calculation: 90 mM change over 2.5 CV, 36 mM / CV). Compared to the reference methods (Sepharose Q XL step elution followed by size exclusion, Figure 3 A and Figure 3 B, Table 4), polishing with Capto core 700 as a second step results in a final batch with significantly reduced debris or impurities as imaged by transmission electron microscopy (TEM). This procedure is expected to perform equally well with gradients of KCl or LiCl, or any combination of NaCl, KCl, and LiCl.

[0105] From the above, it is clearly seen that Method 1 using a combination of Capto Q ImpRes anion exchange resin and Capto Core 700 resin has several advantages over the reference methods.

[0106] On a smaller scale, Method 1 shows clear advantages in impurity reduction. In scaled-up experiments, Method 1 shows better HCP reduction (<LOD vs 22 ng / ml). This feature and other features make the method of the present invention a suitable method for purifying adenovirus vectors for cell therapy.

[0107] Another major benefit of the present invention is that the Capto Core 700 column can be loaded up to 30 column volumes (CV) in Method 1, whereas only 0.2 CV (150 times the loading capacity) can be loaded in the reference method. In addition, the yield is significantly better for the polishing step using shell beads in Method 1 compared to size exclusion chromatography SEC (Table 3).

Claims

1. A method for purifying an adenovirus comprising the steps of: a) capturing an adenovirus from an adenovirus-containing cell culture harvest on an anion exchange resin; b) eluting the adenovirus using a shallow conductivity linear gradient having a salt concentration increasing from 480 mM NaCl to 570 mM NaCl; c) applying the eluted adenovirus to a shell bead resin comprising a porous shell and a porous core, wherein the core is provided with a hydrophobic interaction ligand and the shell is not provided with any ligand; and d) eluting the adenovirus from the shell bead resin into a flow-through, wherein the adenovirus eluted in step d) contains less than 1 ng / ml of host cell protein (HCP), the anion exchange resin is a multimodal Capto Q ImpRes anion exchange resin, and the shell bead resin is a Capto Core 700 resin, and wherein the harvest is a harvest subjected to NFF and TFF in 20 mM Tris, pH 8.0 + 450 mM NaCl.

2. The method according to claim 1, wherein the anion exchange resin is contained in a column and the shell bead resin is contained in another column, and wherein the adenovirus eluted from the anion exchange resin is added to the shell bead resin in a volume corresponding to 15-30 column volumes (CV) of the column containing the shell bead resin.

3. The method according to claim 2, wherein the adenovirus eluted from the anion exchange resin is added to the shell bead resin in a volume corresponding to 25-30 column volumes (CV) of a column comprising the shell bead resin.

4. The method according to any one of claims 1 to 3, wherein the porosity of the core and shell is the same as that of the shell bead resin.

5. The method according to any one of claims 1 to 3, wherein the porosity of the core and shell is different from that of the shell bead resin.

Citation Information

Cited By

  • Method for purifying adenovirus

    CN115627265A